| Category | Oncology |
|---|---|
| Brand | SUTOBUZZ |
| Ingredient | Sunitinib |
| Prescription Required | Yes |
| Strength | 25 mg |
| Package | 28 Capsules |
| Certification | WHO - GMP Certified |
Sunitinib Capsules 25 mg contain sunitinib malate, a targeted kinase inhibitor used in the treatment of specific cancers. Sunitinib is indicated for gastrointestinal stromal tumors (GIST), advanced renal cell carcinoma (RCC), high-risk recurrent RCC following nephrectomy, and certain progressive pancreatic neuroendocrine tumors. The 25 mg strength may be used as part of individualized dosing and dose adjustments based on a patient’s treatment requirements and tolerability. Jasgur LifeScience focuses on supplying quality oncology medicines to pharmaceutical distributors, healthcare providers, and international markets. Sunitinib should be taken only under qualified medical supervision, with appropriate monitoring throughout treatment. Sunitinib Capsules 25 mg in india.
Disclaimer: The information provided on this website is for general informational purposes only and is intended exclusively for healthcare professionals, distributors, wholesalers, hospitals, clinics, pharmacies, and other authorized business entities. Jasgur Life Sciences LLP. does not provide medical advice, prescribe or recommend any medication, or promote self-medication. The use of any medicine or treatment should always be based on the advice and judgment of a qualified healthcare professional. Nothing contained on this website shall be construed as an offer, invitation, or solicitation to sell or supply any product in any jurisdiction where such sale, marketing, distribution, or import is restricted, prohibited, or requires prior regulatory approval. Products protected by valid patent rights are not offered for sale in countries where their sale would constitute patent infringement. Importers, distributors, and buyers are solely responsible for ensuring compliance with all applicable laws, regulations, patent rights, and import requirements in their respective jurisdictions.